Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd has submitted a revised protocol for their Phase 3 clinical trial to the US FDA, marking a significant milestone in their efforts to bring a treatment for knee osteoarthritis to market. The company anticipates beginning patient enrollment in early 2025, pending a smooth review process by the FDA. This development reflects Paradigm’s commitment to advancing their clinical programs and keeping investors informed.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
